In their press statement, Merck said they will submit cladribine for registration in the U.S. and Europe later this year. 默克在其記者發布會上稱，在今年晚些時候，將在美國和歐洲提交克拉屈濱的註冊申請。
Two groups received different doses of cladribine and one group received fake pills. 其中兩組接受不同劑量的克拉屈濱治療，另一組接受安慰劑治療。
滬公網安備 31011502000490號
電信業務許可證編號：滬B2-20190700
